Meanwhile, other pharma companies are also developing checkpoint inhibitors for adjuvant RCC, including Roche ... which is testing its Imfinzi (durvalumab) alone and in combination with CTLA4 ...

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

radiotherapy with adjuvant durvalumab does not improve outcomes over radiotherapy with cetuximab, according to a study published online in the December issue of The Lancet Oncology. Loren K.

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

Medscape Medical News, February 08, 2024 GICS 2024 Durvalumab Plus Bevacizumab ... 2024 GUCS 2024 'Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer KEYNOTE-564 is the first trial ...

Merck (MSD) has released data from the Phase III KEYNOTE-564 clinical trial of KEYTRUDA, an anti-programmed death receptor-1 (PD-1) therapy, for the adjuvant treatment of renal cell carcinoma (RCC ...

The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...